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Abstract
Background: This study of chronically ill patients with schizophrenia aimed to identify patients who achieve
sustained favorable long-term outcome - when the outcome incorporates severity of symptoms, level of
functioning, and use of acute care services - and to identify the best baseline predictors of achieving this sustained
favorable long-term outcome.
Methods: Using data from the United States Schizophrenia Care and Assessment Program (US-SCAP) (N = 2327), a
large 3-year prospective, multisite, observational study of individuals treated for schizophrenia in the US, a
hierarchical cluster analysis was performed to group patients based upon baseline symptom severity. Symptom
severity was assessed using the Positive and Negative Syndrome Scale (PANSS) scores, level of functioning, and use
of acute care services. Level of functioning reflected patient-reported productivity and clinician-rated occupational
role functioning. Use of acute care services reflected self-reported psychiatric hospitalization and emergency service
use. Change of health state was determined over the 3-year period. A patient was classified as having a sustained
favorable long-term outcome if their health state values had the closest distance to the defined “best baseline
cluster” at each point over the length of the study. Stepwise logistic regression was used to determine baseline
predictors of sustained favorable long-term outcome.
Results: At baseline, 5 distinct health state clusters were identified, ranging from “best” to “worst.” Of 1635 patients
with sufficient data, only 157 (10%) experienced sustained favorable long-term outcome during the 2-years
postbaseline. The baseline predictors associated with sustained favorable long-term outcome included better
quality of life, more daily activities, patient-reported clearer thinking from medication, better global functioning,
being employed, not being a victim of a crime, not having received individual therapy, and not having received
help with shopping and leisure activities.
Conclusions: Only a small percentage of patients achieved sustained favorable long-term outcome in this study,
suggesting there continues to be a great need for improvement in the treatment of schizophrenia. Findings
suggest that clinicians could make early projections of health states and identify those patients more likely to
achieve favorable long-term outcomes enabling early therapeutic interventions to enhance benefits for patients.
Background
Heterogeneity of response and outcome is common
among patients treated for schizophrenia [1]. Clinical
study results indicate that about 70% of patients fail to
experience at least minimal efficacy early in treatment
[2,3], and current medications are effective for
approximately 50% of patients [4-6]. Poor efficacy can
lead to early treatment discontinuation, exacerbation of
symptoms, relapse, and increased hospitalization with
higher treatment costs [7-10].
A recent study exploring treatment response trajec-
tories in schizophrenia using data from clinical trials
found that 77% of patients were classified as moderate
responders, 8% as poor responders, and 15% as rapid
responders [11]. A study that used hospitalization as a
proxy measure for psychotic symptom exacerbation over
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a 10-year period found schizophrenia amelioration in
approximately 75% of patients, deterioration in approxi-
mately 25% of patients, and stability in less than 1% of
patients [12]. These results underscore the need to bet-
ter understand patients’ heterogeneity to help improve
patient long-term outcomes.
It has been suggested that the definition of “outcome”
in schizophrenia may need to be broadened beyond
symptom severity to also include quality of life, subjec-
tive well-being, health status, use of healthcare services,
and measures of the patients’ level of functioning
[13-15]. Capturing multiple domains is important to
assess the patient holistically and at varying stages of
the illness. When outcome is broadly defined - beyond
symptom improvement - relatively little is known about
the baseline characteristics that can be used to predict a
favorable long-term outcome among chronically ill
patients with schizophrenia who are treated in usual
care settings.
Using data from a large 3-year observational naturalis-
tic noninterventional study in the United States, this
analysis aimed to identify distinct health states among
chronically ill patients with schizophrenia, using a broad
definition of health state that incorporated severity of
symptoms, level of functioning, and use of acute care
services. Employing these health states, which varied
from “best” to “worst,” the second part of the analysis
aimed to identify patients who achieved sustained favor-
able long-term outcome and the best baseline predictors
of this favorable health state.
Methods
Data Source
The data source for this study was the United States
(US) Schizophrenia Care and Assessment Program
(SCAP), a 3-year prospective, observational study (N =
2327). Participants were adults 18 years and older and
treated for schizophrenia, schizoaffective, or schizophre-
niform disorders, based on Diagnostic and Statistical
Manual of Mental Disorders, fourth edition (DSM-IV)
criteria. The study was conducted between July 1997
and September 2003, and the sample was geographically
and ethnically diverse, representing treatment in large
systems of care. Patients were recruited from commu-
nity mental health centers, university healthcare systems,
community and state hospitals, and the Department of
Veterans Affairs Health Services [16]. The overall objec-
tive of US-SCAP was to better understand the treatment
of patients with schizophrenia in usual care settings.
Patients were excluded if they were unable to provide
informed consent or had participated in a clinical drug
trial within 30 days prior to enrollment. Enrollment was
not contingent upon being treated with a specific anti-
psychotic or with any medication. Patients could
continue with medications they received prior to enroll-
ment for as long as necessary, and decisions about med-
ication changes, if any, reflected those made by
physicians and their patients, as they naturally occur in
usual practice. Almost all study participants were outpa-
tients at the time of enrollment (93.5%). Of 2327 partici-
pants, most completed 1 year of follow-up (78.1%), with
fewer completing 2 years (69.6%) and 3 years (65.2%).
At enrollment, almost all patients (94.7%) were treated
with at least one antipsychotic medication, including
oral typical (36.7%), oral atypical (58.1%), and depot
typical antipsychotics (19.6%). Treatment throughout
the study was based on physicians’ decisions, which
could include medication augmentation, switching, or
discontinuation, reflecting the dynamic antipsychotic
treatment observed in naturalistic care settings. Institu-
tional Review Board (IRB) approval was obtained at
each regional site prior to initiation of the study, and
the study was conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki and are consistent with good clinical practices
and applicable laws and regulations. Informed consent
was received from all participants.
Measures
This study used a number of clinician-rated and patient-
reported measures in addition to patients’ medical
records. Patients’ medical records provided information
about healthcare utilization, such as psychiatric hospita-
lizations and medications (i.e., antipsychotics, antide-
pressants, mood stabilizers, antiparkinsonian agents, and
mood stabilizers). This information was systematically
collected using the Medical Records Abstraction Form
(MRAF). Information about functional and quality-of-
life outcomes was derived from the SCAP Health Ques-
tionnaire (SCAP-HQ) [17]. This 102-item structured
interview was developed for the US-SCAP study and
was administered to patients at enrollment and at 6-
month intervals thereafter. Items for the SCAP-HQ
were drawn from existing measures, such as the Lehman
Quality of Life Interview [18], the Arkansas Schizophre-
nia Outcomes Module [19,20], the Medical Outcome
Study Short Form-12 (SF-12) [21], and the CAGE, a
screening tool for assessment of alcohol-related pro-
blems [22]. The psychometric properties of the SCAP-
HQ were found to be acceptable for application to
large-scale studies in routine care based on a study of
its internal consistency, convergent validity, test-retest
reliability, and responsiveness to change.
Patient symptoms of schizophrenia and depressive
symptoms were assessed annually by a clinician using
the Positive and Negative Syndrome Scale (PANSS) [23]
and the Montgomery-Åsberg Depression Rating Scale
(MADRS) [24], respectively. Clinicians also annually
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assessed medication-emergent adverse events, including
extrapyramidal side effects using the Simpson-Angus
Scale [25] and tardive dyskinesia using the Abnormal
Involuntary Movement Scale (AIMS) [26]. In addition to
using the SCAP-HQ to evaluate both patient-reported
level of functioning and quality of life, clinicians also
used the Global Assessment of Functioning (GAF) [27]
to evaluate level of functioning and the Quality of Life
Scales (QLS) [28] to evaluate quality of life.
Socio-demographic information data were collected at
enrollment and included age, gender, race, marital sta-
tus, education, employment, and insurance status. In
addition, DSM-IV diagnosis of schizophrenia (i.e., schi-
zophrenia, schizoaffective, or schizophreniform) and age
of illness onset were included. The remaining measures
investigated in this analysis are described in Table 1.
The objectives of this study were: 1) to identify
patients with schizophrenia who experience sustained
favorable long-term outcome when the outcome incor-
porates severity of symptoms, level of functioning, and
use of acute care services and 2) to identify the baseline
measures that predict sustained favorable long-term
outcome.
Definition of Schizophrenia Health State and Sustained
Favorable Long-Term Outcome
The first step in this retrospective analysis was to define
each patient’s health state at baseline using symptom
severity, level of functioning, and utilization of acute
care services in a cluster analysis. Symptom severity was
based on PANSS factor subscale scores [29]: PANSS
positive, PANSS negative, PANSS hostility, PANSS dis-
organized thinking, and PANSS anxiety/depression. The
level of functioning reflected patient-reported productiv-
ity (SCAP-HQ; composite measure of reported working
for pay, volunteering, attending school, and keeping
house or taking care of children) and clinician-rated
occupational role functioning (QLS item 9) and level of
accomplishment (QLS item 10). Acute care services
included self-reported psychiatric hospitalization (in the
previous 4 weeks) or use of emergency services (emer-
gency room use in the previous 6 months from the
medical record or self-reported emergency visit with a
psychiatrist in the previous 4 weeks).
Once the health states had been defined by the cluster
analysis, the next step included identifying those with
sustained favorable long-term outcome, which was the
main outcome of interest. A patient was classified as
having sustained favorable long-term outcome if they
were in the “best” cluster (i.e., experienced the lowest
symptom severity and the highest level of functioning)
over a 2-year period postbaseline assessment (from year
1 to year 2 and from year 2 to year 3, as assessments
were conducted annually postbaseline). Change over
time was ascertained by shifts in clusters from baseline
to each postbaseline visit (end of year 1, 2, and 3). The
last step in the retrospective analysis was to identify
baseline measures that were associated with sustained
favorable long-term outcome.
Statistical Methods
As mentioned above, the first step was to define each
patient’s health state at baseline. This was determined
by a hierarchical cluster analysis, using the Ward’s mini-
mum variance method [30], of patients’ schizophrenia
health states to categorize patients into distinct groups
at baseline. Postbaseline clusters were defined by first
performing a principal component analysis on the 10
health state measures for data at baseline and each
postbaseline visit. The “center” for each of the baseline
clusters was defined by computing a mean score for
each of the resulting 10 principal components at base-
line by cluster. Then Euclidean distances were calcu-
lated from the “center” of each of the baseline clusters
to each patient’s 10 principal components at postbase-
line. Finally, each patient’s postbaseline cluster assign-
ment was determined based on their closest Euclidean
distance to each of the clusters at baseline. Patients
were required to have nonmissing data for all health
state measures (i.e., PANSS subscale scores, QLS items
9 and 10, psychiatric hospitalizations, and emergency
services) to be included in the cluster analysis at each
time point.
In addition to characterizing patients by sustained
favorable long-term outcome in the second step of the
analysis, cluster shifts were explored during the three-
year period. Improvement of outcome was based on
changes to a better cluster from baseline to 1-year post-
baseline and maintaining the same improved cluster or
moving to an even better cluster the following 2 years.
Worsening of outcome was based on changes to a
worse cluster from baseline to 1-year postbaseline and
staying in that cluster or shifting to an even worse clus-
ter the following 2 years. Patients who did not experi-
ence improvement or worsening of outcome were
classified as having “no sustained shift in outcome.”
Comparisons of baseline characteristics between
patients with and without sustained favorable long-term
outcome were performed using Fisher’s exact tests (cate-
gorical) and analysis of variance (continuous). Stepwise
logistic regression, following 5 multiple imputations of
missing values, was used to determine baseline factors
associated with sustained favorable long-term outcome.
A total of 62 variables, including the patient-reported
variables, clinician-rated variables, and medical record-
based resource utilization, were explored. The interde-
pendent variables (variance inflation factor > 10) were
removed. A 2-tailed significance level of 0.05 was used
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Table 1 Description of Measures
MEASURE SOURCE DESCRIPTION
SOCIO-DEMOGRAPHICS
Family history Screening
interview
History of emotional or psychiatric illness for any of the following family members:
parent, sibling, child, grandparent, aunt, uncle, cousin, or distant relative
Supervised housing SCAP-HQ Includes in house/apartment where mental health professionals visit, in program with
mental health professionals there most of the time, in a hospital or nursing home, or in
jail or prison
DISEASE-RELATED AND SYMPTOMS
Depression SCAP-HQ Bothered much by feeling low in energy or slowed down, feeling unhappy, sad, or
blue, feeling hopeless about the future, or feeling like a good or worthless person in
the past 4 weeks
MADRS total MADRS Combines apparent sadness, reported sadness, inner tension, reduced sleep, reduced
appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and
suicidal thoughts
Remission PANSS A mild, minimal, or absent response to the lack of spontaneity and flow of
conversation, conceptual disorganization, delusions (general), unusual thought content,
passive/apathetic social withdrawal, hallucinatory behavior, blunted affect, and
stereotyped thinking items of the PANSS
PANSS anxiety/depression (Marder)* PANSS Combines the disorientation, difficulty in abstract thinking, lack of judgment and
insight, and hostility items of the scale
PANSS disorganized (Marder)* PANSS Combines the poor rapport, somatic concern, excitement, tension, mannerisms and
posturing, uncooperativeness, and disturbance of volition items of the scale
PANSS hostility (Marder)* PANSS Combines the anxiety, suspiciousness, emotional withdrawal, and poor attention items
of the scale
PANSS negative (Marder)* PANSS Combines the passive/apathetic social withdrawal, active social avoidance, poor impulse
control, hallucinatory behavior, depression, blunted affect, and preoccupation items of
the scale
PANSS positive (Marder)* PANSS Combines the lack of spontaneity and flow of conversation, conceptual disorganization,
delusions, unusual thought content, guilt feelings, grandiosity, stereotyped thinking, and
motor retardation items of the scale
PANSS Bell factor PANSS Combines the conceptual disorganization, difficult in abstract thinking, lack of judgment
and insight, stereotyped thinking, and poor attention items of the scale
Psychosis SCAP-HQ Bothered much by feeling that others are spying against you or plotting against you,
hearing voices that other people do not hear, feeling like someone is controlling your
thoughts/movements, feeling that you are watched or talked about by others, or
feeling like other people are aware of your private thoughts in the past 4 weeks
Vitality SCAP-HQ Bothered much by feeling low in energy or slowed down in the past 4 weeks
FUNCTIONING/BEHAVIORS
Arrested SCAP-HQ Arrested or picked up for any crime in the past 6 months
Daily Activity SCAP-HQ Frequency of taking responsibility for your laundry, doing or helping with household
chores, preparing at least simple meals, planning or purchasing food and household
items, or shopping for personal necessities in the past 4 weeks
Global assessment of functioning GAF Global assessment of patient functioning rating considering psychological, social, and
occupational functioning on a hypothetical continuum of mental health illness
Health status SCAP-HQ Overall impression of general health (poor, fair, good, very good, or excellent)
Helped by anyone SCAP-HQ Received help with household chores, shopping, paying bills, finding a job, getting
benefits (i.e., SSI, VA, food stamps, other), talking with lawyers, police, fire, or court
officials, or leisure or social activities in the past 4 weeks
Leisure activity SCAP-HQ Went shopping, ate at a restaurant or coffee shop, did something fun (e.g., hobby,
sports, crafts, etc.), or prepared food for yourself in the past 4 weeks
Mental and physical health (SF-12) SCAP-HQ Combines the bodily pain, general health, mental health, physical functioning, role
limitations-emotional, role limitations-physical, social functioning, and vitality domains of
the SF-12 health survey
Productivity* SCAP-HQ Worked at a job for pay, volunteered, attended school, or kept house/took care of
children in the past 4 weeks
Social activity SCAP-HQ Frequency of doing things with friends, doing something with another person that you
planned ahead of time, or spending time with someone more than a friend, boyfriend,
girlfriend, or spouse in the past 4 weeks
Social relationships SCAP-HQ Frequency of doing things with friends or doing something with another person that
you planned ahead of time in the past 4 weeks
Substance abuse SCAP-HQ Frequency of having at least a little to drink or using illegal or “street” drugs in the past
4 weeks
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Table 1 Description of Measures (Continued)
Suicide SCAP-HQ Thought or talked about hurting or killing yourself or actually attempted to hurt or kill
yourself in the past 4 weeks
Victim SCAP-HQ Been a victim of a violent crime (e.g., assault, rape, mugging, or robbery) or nonviolent
crime (e.g., theft or being cheated) in the past 4 weeks
Violent SCAP-HQ Struck or injured someone or threatened to strike or injure someone and meant it in
the past 4 weeks
Satisfaction with basic needs SCAP-HQ Combines the patient’s feeling about the amount of privacy where they live, the way
things are in general between them and their family, and the protection they have
against being robbed or attacked
Satisfaction with social life SCAP-HQ Combines the patient’s feeling about the way they spend their time, the amount of fun
they have, and the amount of friendships in their life
General life satisfaction SCAP-HQ The patient’s feeling about their life in general (combining satisfaction with social life
and basic needs)
Quality of life scale - item 9* QLS Extent of occupational role functioning
Quality of life scale - item 10* QLS Level of accomplishment
Quality of life scale total QLS Combines intimate relationship with household members, intimate relationships with
people other than immediate family or household members, active acquaintances, level
of social activity, involved social network, social initiatives, social withdrawal, socio-
sexual relations, extent of occupational role functioning, level of accomplishment,
degree of underemployment, satisfaction with occupational role functioning, sense of
purpose, degree of motivation, curiosity, anhedonia, time utilization, commonplace
objects, commonplace activities, capacity for empathy, and capacity for engagement
and interaction with interviewer
HEALTHCARE RESOURCE UTILIZATION
Case management MRAF Case management (documented in medical record within the past 6 months)
Crisis call SCAP-HQ Called a crisis hotline in the past 4 weeks
Emergency service use* SCAP-HQ
MRAF
Had an unscheduled emergency visit with a psychiatrist or therapist in the past 4
weeks
Emergency room visit (past 6 months)
Individual therapy MRAF Received individual therapy (past 6 months)
Number of hospitalizations/total number of
days hospitalized (6 months)
MRAF Used admission and discharge dates reported on the medical record extraction form
Psychiatric hospitalizations (4 weeks)* SCAP-HQ Stayed overnight in a hospital for a mental or emotional problem
Psychiatric hospitalizations (1 year) Screening
interview
Been in the hospital for a mental or emotional problem in the last year
MEDICATION ADHERENCE
Medication possession ratio MRAF The cumulative number of days the patient had been prescribed any antipsychotic
drug divided by the number of days in the assessment period multiplied by 100
Non-adherence SCAP-HQ How regularly did the patient take the medication they were given for mental,
emotional, or nervous problems in the past 4 weeks
MEDICATION-EMERGENT EVENTS
Level of abnormal involuntary movements AIMS Combines facial and oral movements (muscles of facial expression, lips and perioral
area, jaw, tongue), extremity movements (upper [arms, wrists, hands, fingers], lower
[legs, knees, ankles, toes]), and trunk movements (neck, shoulders, hips)
Clearer thoughts from medication SCAP-HQ Current medication for mental, emotional, or nervous problem is making your thoughts
clearer
Medication effects SCAP-HQ Current medication for mental, emotional, or nervous problem is making your thoughts
clearer, making you feel tired and sluggish, interfering with your normal thinking,
making you feel restless, or interfering with your normal sexual functioning
Tardive dyskinesia AIMS A response of moderate or severe on either facial and oral movements (muscles of
facial expression, lips and perioral area, jaw, tongue), extremity movements (upper
[arms, wrists, hands, fingers], lower [legs, knees, ankles, toes]), or trunk movements
(neck, shoulders, hips) or a response of mild, moderate, or severe on any 2 of the
previous items
Psuedo-parkinsonian symptoms SA Combines gait, arm dropping, shoulder shaking, elbow rigidity, fixation of position or
wrist rigidity, leg pendulousness, glabella tap, tremor, and salivation
Restlessness SCAP-HQ Medication for mental, emotional, or nervous problem is making you feel restless
Abbreviations: AIMS = abnormal involuntary movement scale, BDCF = baseline demographic collection form, GAF = global assessment form, MADRS =
Montgomery-Åsberg depression rating scale, MRAF = medical record assessment form, PANSS = positive and negative syndrome scale, QLS = quality of life scale,
SA = Simpson-Angus scale, SCAP-HQ = schizophrenia care and assessment program-health questionnaire; SF = short form.
* Measures used in the schizophrenia health state definition.
NOTE: The various patient-reported and clinician reported measures in addition to the items obtained from the medical records investigated in this analysis.
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to determine whether a baseline measure was included
in or excluded from the model.
Results
Most (83% or 1942/2327) study enrollees had sufficient
baseline data for inclusion in the cluster analysis. A
baseline comparison of the patients included in the clus-
ter analysis and those not included revealed that the
included patients were significantly older (42.2 years
versus 40.3 years; p = .0029) and less likely to be unem-
ployed (77.6% versus 83.4%; p = .0122) and had lower
PANSS positive scores (17.9 versus 19.5; p < .0001),
lower PANSS negative scores (17.8 versus 19.1; p =
.0002), lower PANSS hostility scores (10.4 versus 11.3; p
< .0001), lower PANSS anxiety/depression scores (10.4
versus 11.2; p < .0001), and higher GAF scores (43.7
versus 33.7; p < .0001).
There were 5 distinct health state clusters identified
(Table 2) in the first step of the analysis and labeled
from the “best” to “worst” cluster, with severity of symp-
toms and level of functioning influencing cluster order.
The majority of patients (77%) belonged to either the
“best” (n = 503) or the “second best” (n = 992) clusters
at baseline. Although the average symptom severity and
level of functioning was worse for patients in the
“worst” cluster, all of the acute care services were
experienced by patients in the “middle” and “second
worst” groups.
Approximately 70% of the patients had postbaseline
data to examine sustained favorable long-term outcome
for the second step of the analysis. A baseline compari-
son of these patients (n = 1635) and those not included
(n = 692) revealed that the included patients were older
(42.3 years versus 40.8 years; p = .0039), had higher
PANSS positive scores (18.5 versus 17.3; p < .0001),
higher PANSS negative scores (18.3 versus 17.3; p =
.0007), higher PANSS disorganized scores (13.7 versus
12.8; p < .0001), higher PANSS hostility scores (10.8
Table 2 Baseline Characteristics for Variables Used to Define Health States by Cluster (n = 1942)
Cluster Variables Best
n = 503
Second Best
n = 992
Middle
n = 145
Second Worst
n = 53
Worst
n = 249
Total
(n = 1942)
SYMPTOM SEVERITYa
PANSS positive,
mean (sd)
13.81 (3.92) 18.02 (5.38) 19.24 (6.70) 19.72 (6.32) 24.34 (5.27) 17.88 (6.05)
PANSS negative,
mean (sd)
13.17 (4.06) 17.98 (5.33) 20.08 (6.48) 20.17 (5.99) 24.54 (5.77) 17.79 (6.25)
PANSS hostility,
mean (sd)
7.77 (2.43) 10.57 (3.35) 11.53 (3.86) 12.08 (3.10) 14.32 (2.79) 10.44 (3.68)
PANSS disorganized thinking,
mean (sd)
10.66 (2.67) 12.99 (3.64) 13.89 (4.65) 14.43 (3.80) 19.75 (3.97) 13.36 (4.46)
PANSS anxiety/depression 8.61 (2.88) 10.51 (3.06) 9.91 (3.16) 10.76 (3.36) 13.61 (3.10) 10.38 (3.37)
FUNCTIONING
Occupational role functioning (QLS 9), mean (sd) 3.59 (1.55) 1.66 (1.62) 1.65 (1.73) 1.34 (1.34) 0.46 (0.80) 1.99 (1.83)
Level of accomplishment (QLS 10), mean (sd) 4.39 (1.08) 2.07 (1.54) 2.10 (1.84) 1.58 (1.41) 0.68 (0.91) 2.48 (1.84)
Productivity, n (%) 503 (100%) 605 (61) 90 (62.1) 38 (71.7) 92 (36.9) 1328 (68.4)
ACUTE CARE
Emergency useb, n (%) 0 0 145 (100) 18 (34) 0 163 (8.4)
Psychiatric hospitalizations,
(past 4 weeks), n (%)
0 0 0 53 (100) 0 53 (2.7)
Abbreviations: n = number of patients; PANSS = positive and negative syndrome scale; QLS = Quality of Life Scale; sd = standard deviation.
a PANSS factors per Marder et al. (1997) [29]
b Emergency use was both patient reported for the past 4 weeks and from the past 6 months recorded in the medical record.
NOTE: There were 5 distinct outcome clusters identified and labeled from the “best” to “worst” cluster, with severity of symptoms and level of functioning
influencing cluster order. The majority of patients (77%) belonged to either the “best” (n = 503) or the “second best” (n = 992) clusters at baseline.
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versus 10.2; p = .0004), lower GAF scores (41.6 versus
43.3; p = .0063), and lower mean QLS total scores (2.8
versus 3.0; p = .0216). Of the 1635 patients included in
the analysis, 369 (23%) were closest to the “best” cluster
at year 1; 209 (13%) achieved favorable outcome over 1
year (from year 1 to year 2); and 157 (10%) achieved
favorable sustained outcome over 2 years (from year 1
to year 3) (Figure 1).
An assessment of cluster shift over time was con-
ducted to further understand change over the 3-year
period, and patients were classified as “improved,” “wor-
sened,” or “no sustained shift of health state.” Most
patients (85%; n = 688) showed “no sustained shift,”
while 10% (n = 84) showed “improved” health state and
only 4% (n = 34) had “worsened” over the length of the
study.
The comparison of baseline characteristics for patients
with and without sustained favorable long-term outcome
over the 2-year postbaseline period are shown in Table
3. In general, the univariate analyses showed that
patients with sustained favorable long-term outcome
started out better compared with those without sus-
tained favorable long-term outcome. At baseline, they
were significantly more likely to have fewer symptoms,
higher level of functioning, better quality of life, satisfac-
tion with life, fewer medication-emergent events, and
lower healthcare resource utilization.
When assessing the association (OR [95% CI])
between all baseline measures and sustained favorable
long-term outcome in the last step of the analysis, only
9 variables remained statistically significant (Figure 2).
Patients who were employed (1.98 [1.34, 2.91]),
shopped without receiving assistance (1.76 [1.19,
2.59]), and engaged in leisure activities without receiv-
ing assistance (1.75 [1.10, 2.79]) had significantly
greater odds of experiencing sustained favorable long-
term outcome, while those who received individual
therapy (0.47 [0.25, 0.88]) and were victims of a violent
or non-violent crime (0.38 [0.17, 0.85])had significantly
lower odds of experiencing sustained favorable long-
term outcome. In addition, patients experiencing
clearer thoughts from their medication (1.21 [1.04,
1.40]), a better quality of life (mean QLS total score:
1.64 [1.32, 2.03]), better global functioning (1.04 [1.02,
1.06]), and more daily activities (1.27 [1.06, 1.52]) had
significantly greater odds of experiencing sustained
favorable long-term outcome.
Discussion
Using data from a large 3-year prospective observational
study, this analysis identified 5 distinct health state clus-
ters among chronically ill patients with schizophrenia
treated in usual care settings in the US. This analysis
incorporated its definition of patients ’ health state,
severity of symptoms level of functioning, and use of
acute care services, thus reflecting a broader health state
concept that is not confined to symptomatology alone.
Although the concept of broadening the definition of
outcome has been utilized in a few prior schizophrenia
studies, these studies have incorporated only patient’s
level of functioning along with symptoms [13-15]. To
our knowledge, incorporating the patient’s use of acute
care services, severity of symptoms, and level of function
has not been previously explored in the literature and
provides a holistic view of the health status of the
patient.
In this study, only 10% of the patients achieved “sus-
tained favorable long-term outcome” over a 2-year per-
iod. A further assessment of cluster shift over the 3-year
study period showed that a few patients (10%) improved
over time (based on the definition of sustained favorable
outcome), while the majority of patients (85%) had no
sustained change from baseline in health state. Current
findings suggest there continues to be a great need for
improvement in the health status, and thus the need for
better treatments, of these chronically ill patients with
schizophrenia. This is a consistent message from past
research, although this current study shows that a rather
small percentage of patients are achieving “sustained
long-term favorable outcome.” Past research, which used
a different definition of outcome and a different study
Abbreviation:  FLO = Favorable long-term outcome 
Patients with post -
baseline data 
N=1635
Yes
n=369 (23%) 
No 
n=1056 (65%) 
Missing 
n=210 (13%) 
FLO* from year 1 to year 2 post baseline
Yes 
n=209 (13%) 
No 
n=140 (9%) 
Missing 
n=20 (1%)
Yes 
n=157 (10%) 
No 
n=52 (3%) 
Closest to “best” cluster at year 1 
FLO* from year 2 to year 3 post baseline 
Figure 1 Favorable long-term outcome (FLO*) over time. Of the
1635 patients included in the analysis, 369 (23%) were closest to
the “best” cluster at year 1; 209 (13%) achieved favorable outcome
over 1 year (from year 1 to year 2); and 157 (10%) achieved
favorable sustained outcome over 2 years (from year 1 to year 3).
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Table 3 Baseline Characteristics by Sustained Favorable Long-Term Outcome (N = 1635)
SUSTAINED FAVORABLE LONG-TERM OUTCOME
Yes
n = 157
No
n = 1478
Univariate
p value
SOCIO-DEMOGRAPHICS
Age, mean (sd) 42.09 (10.61) 42.31 (11.00) .8182
Male, n (%) 77 (49.0) 924 (62.5) .0010
Race/ethnicity, n (%)
Caucasian 86 (54.8) 800 (54.1) .7398
African-American 61 (38.9) 538 (37.8)
Other 10 (6.4) 120 (8.1)
Single marital status, n (%) 142 (91.0) 1324 (90.2) .7380
High school education or less, n (%) 43 (27.6) 508 (34.6) .0774
Employed, n (%) 66 (42.0) 271 (18.4) <.0001
Lack of health insurance, n (%) 20 (12.7) 78 (5.3) .0002
Family history, n (%) 80 (55.2) 776 (56.7) .7198
Supervised housing, n (%) 24 (15.3) 483 (33.2) <.0001
DISEASE-RELATED AND SYMPTOMS
Age at illness onset, mean (sd) 21.50 (9.33) 19.97 (8.70) .0446
Depression, mean (sd) 2.01 (0.88) 2.41 (1.01) <.0001
MADRS total score, mean (sd) 9.89 (8.79) 14.68 (10.26) <.0001
PANSS positive (symptoma), mean (sd) 14.89 (5.10) 18.84 (6.08) <.0001
PANSS negative (symptoma), mean (sd) 14.10 (5.00) 18.72 (6.18) <.0001
PANSS hostility (symptoma), mean (sd) 8.52 (3.40) 10.99 (3.63) <.0001
PANSS disorganized (symptoma), mean (sd) 11.36 (3.51) 13.92 (4.52) <.0001
PANSS anxiety/depression (symptoma), mean (sd) 9.02 (2.93) 10.71 (3.41) <.0001
Remission (PANSS), n (%) 66 (43.1) 293 (20.0) <.0001
PANSS total score, mean (sd) 57.79 (15.54) 72.58 (18.22) <.0001
PANSS Bell factor, mean (sd) 11.22 (4.32) 13.78 (5.01) <.0001
Psychosis, mean (sd) 1.63 (0.84) 2.01 (1.05) <.0001
Vitality, mean (sd) 3.55 (1.17) 3.19 (1.29) .0008
FUNCTIONING/BEHAVIORS
Daily activities, mean (sd) 3.95 (0.95) 3.30 (1.21) <.0001
Leisure activities, mean (sd) 3.18 (0.97) 2.64 (1.19) <.0001
Social activities, mean (sd) 2.96 (0.98) 2.62 (1.06) .0001
Social relationships, mean (sd) 3.17 (1.10) 2.82 (1.23) .0005
Arrestedc, n (%) 4 (2.5) 79 (5.4) .1268
Violence, n (%)
No thought of injuring anyone 152 (96.8) 1372 (93.1) .0358
Thoughts of injuring someone 0 60 (4.1)
Have injured someone 5 (3.2) 42 (2.8)
Victim of a crime, n (%) 8 (5.1) 166 (11.3) .0170
Suicide thought/attempt, n (%) 18 (11.5) 249 (16.9) .0789
Substance use, n (%) 44 (28.0) 386 (26.2) .6262
Received helped with shopping, n (%) 59 (37.6) 840 (57.1) <.0001
Received helped with leisure, n (%) 28 (17.8) 478 (32.5) .0002
Received helped with household chores, n (%) 70 (44.6) 790 (53.6) .0309
Received helped with paying bills, n (%) 77 (49.0) 899 (61.1) .0035
Received helped with job search, n (%) 29 (18.5) 246 (16.8) .5940
Received helped with getting benefits, n (%) 39 (25.2) 472 (32.1) .0782
Received helped with legal issues, n (%) 11 (7.1) 142 (9.7) .3046
General life satisfaction, mean (sd) 5.02 (1.47) 4.53 (1.59) .0002
Satisfaction with basic needs, mean (sd) 5.23 (1.04) 4.71 (1.12) <.0001
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duration, has have shown that current medications are
effective for only approximately 50% of patients [4-6].
Our findings may reflect a somewhat conservative
definition of “favorable and sustained long-term out-
come,” considering we required patients to be closest to
the best baseline health status cluster in each of the 2
years following the initial cluster assignment baseline
assessment. Therefore, there is the possibility that more
than 10% of patients have improved, just not to the
degree defined in this study as “sustained favorable
long-term outcome.”
Importantly, this study identified a small set of base-
line characteristics that predict long-term sustained
favorable health states over the study period. These
characteristics included better quality of life, more daily
activities, patient-reported clearer thinking from medica-
tion, better global functioning, being employed, not
receiving individual therapy, not being a victim of a
Table 3 Baseline Characteristics by Sustained Favorable Long-Term Outcome (N = 1635) (Continued)
Satisfaction with social life, mean (sd) 5.08 (0.85) 4.57 (1.05) <.0001
SF 12-Mental Health, mean (sd) 45.22 (12.44) 40.45 (13.34) <.0001
SF 12-Physical Health, mean (sd) 47.70 (11.29) 45.17 (12.99) .0192
Occupational role functioning (QLS 9), mean (sd) 3.15 (1.88) 1.76 (1.73) <.0001
Level of accomplishment (QLS 10), mean (sd) 3.86 (1.61) 2.23 (1.77) <.0001
Mean QLS total, mean (sd) 3.71 (1.06) 2.74 (1.01) <.0001
Global Assessment of Functioning (GAF), mean (sd) 52.59 (13.74) 40.48 (12.09) <.0001
Overall impression of general health
(good/very good/excellent), n (%)
116 (73.9) 885 (60.2) .0008
Productivity, n (%) 138 (87.9) 916 (62.1) <.0001
MEDICATION ADHERENCE
Medication possession ratio < .80, n (%) 21 (13.9) 140 (9.9) .1274
Non-adherence, n (%) 6 (3.9) 110 (7.6) .0909
MEDICATION-EMERGENT EVENTS
AIMS total, mean (sd) 2.28 (3.16) 3.52 (4.20) .0005
Simpson-Angus totald, mean (sd) 2.93 (3.41) 4.61 (4.20) <.0001
Patient-reported clearer thoughts from medication, mean (sd) 3.74 (1.19) 3.22 (1.35) <.0001
Medication effects, mean (sd) 1.83 (0.63) 2.07 (0.75) .0001
Restlessness, mean (sd) 1.68 (1.13) 1.87 (1.17) .0533
Tardive dyskinesia, n (%) 33 (22.1) 489 (34.3) .0027
CONCOMITANT MEDICATION
Mood stabilizers, n (%) 35 (22.7) 469 (32.3) .0145
Antidepressants, n (%) 58 (37.7) 573 (39.5) .6541
Antiparkinsonians, n (%) 64 (41.6) 672 (46.3) .2571
Anti-anxiety medications, n (%) 12 (7.8) 171 (11.8) .1376
HEALTHCARE RESOURCE UTILIZATION
Emergency service use b (acute care service), n (%) 11 (7.0) 174 (11.8) .0711
Psychiatric hospitalization (acute care service) (past 4 weeks), n (%) 7 (4.5) 134 (9.1) .0494
Number of hospitalizations (6 months), mean (sd) 0.13 (0.36) 0.31 (0.66) .0010
Total number of days hospitalized (6 months), mean (sd) 2.29 (13.84) 5.82 (21.58) .0453
Psychiatric hospitalizations (1-year), n (%) 34 (21.8) 509 (34.8) .0011
Crisis call 2 (1.3) 73 (5.0) .0362
Case Management d, n (%) 5 (50.0) 190 (68.6) .2158
Individual therapy, n (%) 139 (89.1) 1378 (94.1) .0145
Abbreviations: AIMS = Abnormal Involuntary Movement Scale; MADRS = Montgomery-Åsberg Depression Rating Scale; n = number of patients; PANSS = positive
and negative syndrome scale; QLS = Quality of Life Scale; sd = standard deviation; SF = short form.
a PANSS factors per Marder et al. (1997) [29]
b Emergency use was both patient reported for the past 4 weeks and from the past 6 months recorded in the medical record.
c The variation inflation factor for the arrested measure was greater than 10 and therefore not included in the stepwise logistic regression model.
d Measure was not included in the stepwise logistic regression due to missing data.
NOTE: The univariate comparison of baseline characteristics for patients with and without sustained favorable long-term outcome over the 2-year postbaseline
period.
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crime, and receiving less help with shopping or leisure
activities. In general, when exploring baseline factors
that were associated with sustained favorable long-term
outcome, patients with a less severe illness profile (i.e.,
quality of life and functioning) were more likely to sub-
sequently experience the favorable outcome of interest.
Results of this study are consistent with prior research
using data from patients in clinical trial settings, which
found that patients with a less severe illness profile at
baseline (e.g., higher level of functioning) had more
favorable outcomes [14,31]. A naturalistic study [15]
also confirmed that characteristics of those patients who
were functioning better at baseline was predictive of
functional remission.
Of particular interest, the results indicate that more
daily activities and receiving less help with shopping or
leisure activities were associated with sustained favorable
long-term outcome. These factors are potentially modifi-
able and easy to assess, thus enabling clinicians to better
understand and help optimize the treatment plan for
the patient.
Although prior studies utilized varying endpoints,
methods, and research designs, results appear similar to
the present study in that patients who had better base-
line profiles appeared to have better outcomes. The pre-
sent study expands on past research by exploring
potential predictors of sustained favorable long-term
outcome and by using a broadly defined outcome mea-
sure that combines symptom severity, level of function-
ing, and use of acute care sevices. Moreoever, since data
from randomized controlled trials provide efficacy data
in a relatively homogenous population under artifical
circumstances, it is reassuring to find that these results
are confirmed in usual practice real-world settings. The
identification of predictors of favorable outcomes sug-
gests that clinicians could make early projections of
health states and identify those patients more likely to
achieve favorable long-term outcomes, enabling early
therapeutic interventions to enhance benefits for
patients.
This study has a number of limitations, including
infrequent assessments. Clinician-reported outcomes
were obtained only annually, and patient-reported out-
comes were assessed every 6 months. Due to the infre-
quent assessments and the fact that schizophrenia is an
illness characterized by relapses and remissions, this
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Mean QLS total score
Clearer thoughts
Global functioning
Employed
Received individual therapy
Did not need help with shopping
Did not need help with leisure acitivities
Victim of a crime
Mean QLS total score
Daily activitiesDaily activities
Patient-reported clearer thoughts from medication
Global assessment of functioning (GAF)
Employed
Received individual therapy
Did not receive help with shopping
Did not receive help with leisure activities
Victim of a crime
Lesser Odds                                                                Greater Odds
Odds Ratios (95% CI)
Abbreviation:  QLS = Quality of Life Scale. 
Figure 2 The best baseline predictors of sustained favorable long-term outcome over a 3-year period. When assessing the association
between all baseline measures and sustained favorable long-term outcome, only 9 variables remained statistically significant.
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study was unable to capture episodic exacerbations or
relapses that may have occured between assessments.
Because of these infrequent assessments, other changes
within those time periods and the potentially important
variable of patients’ early response to therapy were not
captured. Lack of early response (week 2) has been
found to be an important predictor [2,3] of subsequent
response to therapy. There may be additional predictors
not assessed, thus not explored, such as premorbid
functioning, that may play an important role in patients’
long-term outcomes. Also, p-values presented in the
univariate analysis results were not adjusted for multiple
comparisons. This study was intended for hypothesis
generating as opposed to confirmation of a hypothesis,
so the results would need to be replicated in a different
study. Further, due to the statistical modeling of a large
number of potential predictors and the method used for
that analysis, we employed multiple imputation methods
for missing data to reduce the number of observations
deleted from the analysis. While the analysis included
most (83%) of the enrolled patients, the patients who
were included in the baseline cluster analysis were
found to have a milder illness profile compared with
those who were excluded, and the likely impact on the
current results is unknown.
Conclusions
This naturalistic, observational, 3-year study of chroni-
cally ill patients with schizophrenia identified 5 distinct
health state clusters, which incorporate patients’ baseline
symptom severity, level of functioning, and use of acute
care services. Using these health states, this study identi-
fied a small set of baseline characteristics that best pre-
dict sustained favorable long-term outcome over a 2-year
postbaseline period. Findings may help clinicians tailor
treatment alternatives that best meet individual patients’
long-term needs. Understanding what factors may pre-
dict better long-term outcomes may also direct additional
therapeutic options, enabling a holistic approach to treat-
ing patients and optimizing the potential benefit. Addi-
tional research building upon the current findings may
allow for identification of early therapeutic interventions
that could enhance patients’ likelihood of achieving sus-
tained favorable long-term outcomes.
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